Clinical Trial Update: A Phase 3 Study to Evaluate the Safety and Efficacy L606 in Participants With PH-ILD [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial is evaluating the safety and efficacy of L606 for pulmonary hypertension due to lung disease (PH-ILD) and is currently not yet recruiti…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Hypertension Due to Interstitial Lung Disease
• Pulmonary Hypertension Due to Lung Disease

Drugs mentioned

• L606

Snippet

Sponsor: Liquidia Technologies, Inc. | Conditions: Pulmonary Hypertension Due to Lung Disease (Disorder) | Phase 3 | Status: NOT_YET_RECRUITING